ARISTO2024-07-012024-09-30 ARISTO2024-07-012024-09-30in-bse-fin:OneOperatingExpenses01Member ARISTO2024-09-30 ARISTO2024-07-012024-09-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares ARISTO NOTLISTED INE082101010 Aristo Bio-Tech And Lifescience Limited Nonbanking Format SME/ITP 2024-04-01 2025-03-31 2024-11-14 2024-11-08 INR Lakhs Half yearly Single segment Manufacturing,supply,Formulation etc of Agrochemical Products 18:30:00 19:10:00 2024-11-14 2024-11-14 true Cash Flow Indirect Not applicable 2024-04-01 2024-09-30 Unaudited Standalone 2141459000.00 2252000.00 2143711000.00 1970151000.00 0.00 3451000.00 19292000.00 10207000.00 12860000.00 67066000.00 2083027000.00 60684000.00 0.00 60684000.00 0.00 60684000.00 12376000.00 2774000.00 15150000.00 45534000.00 0.00 0.00 0.00 45534000.00 45534000.00 68078000.00 10 6.69 6.69 0.00 0.00 0.00 1. The above results have been reviewed by the Audit Committee and Subsequently approved by the Board of Directors on 14th November, 2024 2. The figures have been regrouped/ rearranged wherever necessary to make them comparable with the current period figures 3.Company is engaged in providing Best Quality manufacturing, formulation, supply and packaging, job work services for various Pesticides: Insecticides, Herbicides, Fungicides, Plant Growth Regulators and a wide variety of other Agrochemicals in India as well as for Export. 4.The company has only single reportable business segment and hence, seprate information for segment wise disclosure is not applicable in accordance with the requirements of accounting standard (AS) 17. 5. IND AS is not currently applicable to the company hence the statement is prepared in accordance with the requirement of Accounting Standards (AS) specified under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014. 6. The figures for half year ended on 31.03.2024 are the balancing figures between audited figures in respect of year ended 31.03.2024 and unaudited figures for the half year ended on 30.09.2023 7 . Earning per Equity Share (EPS) is calculated on the weighted average share capital 8.he Status of Investor's complaints during the half year ended 30th September, 2024 as under:NIL 9. Contigent liability included Bank Guarantee provided to customer, contracts to be executed by company and Outstanding tax demand in respect of Sales Tax not considered as debt. Other Expenses 67066000.00 68078000.00 313542000.00 381620000.00 0.00 0.00 84781000.00 3911000.00 0.00 88692000.00 118353000.00 76292000.00 1542159000.00 5380000.00 20337000.00 1762521000.00 2232833000.00 231768000.00 9000.00 231777000.00 0.00 6525000.00 238302000.00 0.00 447127000.00 1422740000.00 7807000.00 0.00 113166000.00 3691000.00 1994531000.00 2232833000.00 0.00 12860000.00 0.00 0.00 0.00 0.00 0.00 0.00 9520000.00 0.00 22380000.00 -45261000.00 -848011000.00 -49567000.00 923464000.00 379000.00 2995000.00 -16001000.00 6379000.00 67063000.00 0.00 0.00 -199000.00 15150000.00 0.00 51714000.00 0.00 0.00 51714000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3001000.00 30147000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 199000.00 0.00 -715000.00 0.00 -27662000.00 0.00 0.00 -27662000.00 0.00 0.00 0.00 0.00 15183000.00 0.00 11154000.00 0.00 3722000.00 -22615000.00 0.00 0.00 -22615000.00 1437000.00 0.00 1437000.00 6370000.00 7807000.00